Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TAK and other ETFs, options, and stocks.

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. 

CEO
Christophe Weber
CEOChristophe Weber
Employees
47,455
Employees47,455
Headquarters
Osaka, Osaka
HeadquartersOsaka, Osaka
Founded
1781
Founded1781
Employees
47,455
Employees47,455

TAK Key Statistics

Market cap
54.16B
Market cap54.16B
Price-Earnings ratio
69.29
Price-Earnings ratio69.29
Dividend yield
3.48%
Dividend yield3.48%
Average volume
4.01M
Average volume4.01M
High today
$17.20
High today$17.20
Low today
$16.80
Low today$16.80
Open price
$17.09
Open price$17.09
Volume
2.42M
Volume2.42M
52 Week high
$17.26
52 Week high$17.26
52 Week low
$12.99
52 Week low$12.99

TAK News

TipRanks 2h
Takeda Advances TAK-279 in Ulcerative Colitis: What Investors Should Watch Next

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Study Overview: Takeda is running a Phase 2 study called “A Phase 2, M...

TipRanks 2h
Takeda’s TAK-781 Trial Moves Forward in Rare Liver Disease, Quietly Building Long-Term Pipeline Value

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda Pharmaceutical is advancing a new early-stage study of TAK-781,...

TipRanks 1d
Takeda’s Zasocitinib Trial in Psoriatic Arthritis Moves Forward, Raising New Pipeline Upside

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda is advancing a key late-stage study for its oral drug zasocitin...

Analyst ratings

53%

of 15 ratings
Buy
53.3%
Hold
46.7%
Sell
0%

More TAK News

TipRanks 1d
Takeda Deepens Real-World Safety Data for Adzynma in Ultra-Rare cTTP Market

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Study Overview This post-authorization safety study, officially title...

Benzinga 1d
Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a third-quarter 2025 adjusted net profit of 235 billion Japanese yen (approximately $1.53 billion). The...

Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control
TipRanks 1d
Takeda raises FY25 core EPS view to 486 yen from 479 yen

Raises FY25 revenue view to 4.53B yen from 4.5B yen. The company said, “Takeda (TAK) has updated its full year Management Guidance for Revenue primarily due to...

TipRanks 1d
Takeda Posts Lower Nine-Month Revenue but Higher Profit, Lifts Dividend and Trims Growth Outlook

Takeda Pharmaceutical Co ( (JP:4502) ) has shared an update. Takeda reported a 3.3% year-on-year decline in revenue to ¥3.41 trillion for the nine months ended...

TipRanks 2d
Takeda’s Phase 3 Mezagitamab Trial in ITP Moves Forward, Keeping Pipeline Hopes in Focus

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Study Overview Takeda is running a late-stage Phase 3 trial called “A...

TipRanks 2d
Takeda’s TAK-330 Nears Key Milestones in High-Stakes Emergency Surgery Trial

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda is running a Phase 3 trial to test TAK-330, a drug designed to...

TipRanks 4d
Takeda’s GATTEX Safety Survey: What an Ongoing REMS Study Signals for Investors

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview: Takeda is running an o...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.